Chun Shing Kwok1, Evangelos Kontopantelis2, Vijay Kunadian3, Simon Anderson1, Karim Ratib4, Mathew Sperrin5, Azfar Zaman5, Peter F Ludman6, Mark A de Belder6, James Nolan4, Mamas A Mamas7. 1. Cardiovascular Research Group, Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom. 2. Farr Institute, University of Manchester, Manchester, United Kingdom. 3. Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom. 4. Royal Stoke Hospital, University Hospital North Midlands, Stoke-on-Trent, United Kingdom. 5. Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom. 6. The James Cook University Hospital, Middlesbrough, United Kingdom. 7. Farr Institute, University of Manchester, Manchester, United Kingdom; Royal Stoke Hospital, University Hospital North Midlands, Stoke-on-Trent, United Kingdom; Cardiovascular Research Group, Institutes of Science and Technology in Medicine and Primary Care, Keele University, Staffordshire, United Kingdom. Electronic address: mamasmamas1@yahoo.co.uk.
Abstract
BACKGROUND: Gender is a strong predictor of periprocedural major bleeding complications after percutaneous coronary intervention (PCI). The access site represents an important site of such bleeding complications, which has driven adoption of the transradial access (TRA) use during PCI, although female gender is an independent predictor of transradial PCI failure. This study sought to define gender differences in access site practice and study associations between access site choice and clinical outcomes for PCI over a 6-year period, through the analysis of the British Cardiovascular Intervention Society observational database. METHODS AND RESULTS: In-hospital major adverse cardiovascular events (a composite of in-hospital mortality and in-hospital myocardial reinfarction and target vessel revascularization), in-hospital bleeding complications, and 30-day mortality were studied based on gender and access site choice (transfemoral access, TRA) in 412,122 patients who underwent PCI between 2007 and 2012 in the United Kingdom. Use of TRA increased in both genders over time, although this lagged behind in women (21% in 2007 to 58% in 2012) compared with men (24% in 2007 to 64% in 2012). In both men and women, TRA was independently associated with a lower in-hospital major adverse cardiovascular event (odds ratio [OR] 0.82, 95% CI 0.76-0.90; OR 0.75, 95% CI 0.66-0.84), in-hospital major bleeding (OR 0.54, 95% CI 0.44-0.66; OR 0.26, 95% CI 0.20-0.33), and 30-day mortality (OR 0.80, 95% CI 0.73-0.89; OR 0.82, 95% CI 0.71-0.94), respectively. CONCLUSIONS: Where possible, TRA should be considered as the preferred access site choice for PCI, particularly in women in whom the greatest reductions bleeding end points were observed across all indications.
BACKGROUND: Gender is a strong predictor of periprocedural major bleeding complications after percutaneous coronary intervention (PCI). The access site represents an important site of such bleeding complications, which has driven adoption of the transradial access (TRA) use during PCI, although female gender is an independent predictor of transradial PCI failure. This study sought to define gender differences in access site practice and study associations between access site choice and clinical outcomes for PCI over a 6-year period, through the analysis of the British Cardiovascular Intervention Society observational database. METHODS AND RESULTS: In-hospital major adverse cardiovascular events (a composite of in-hospital mortality and in-hospital myocardial reinfarction and target vessel revascularization), in-hospital bleeding complications, and 30-day mortality were studied based on gender and access site choice (transfemoral access, TRA) in 412,122 patients who underwent PCI between 2007 and 2012 in the United Kingdom. Use of TRA increased in both genders over time, although this lagged behind in women (21% in 2007 to 58% in 2012) compared with men (24% in 2007 to 64% in 2012). In both men and women, TRA was independently associated with a lower in-hospital major adverse cardiovascular event (odds ratio [OR] 0.82, 95% CI 0.76-0.90; OR 0.75, 95% CI 0.66-0.84), in-hospital major bleeding (OR 0.54, 95% CI 0.44-0.66; OR 0.26, 95% CI 0.20-0.33), and 30-day mortality (OR 0.80, 95% CI 0.73-0.89; OR 0.82, 95% CI 0.71-0.94), respectively. CONCLUSIONS: Where possible, TRA should be considered as the preferred access site choice for PCI, particularly in women in whom the greatest reductions bleeding end points were observed across all indications.
Authors: Shariq Shamim; Fengming Tang; David Safley; Philip Jones; John A Spertus; Dmitri Baklanov Journal: Am J Cardiol Date: 2017-03-30 Impact factor: 2.778
Authors: Melissa M Farmer; Maggie A Stanislawski; Mary E Plomondon; Bevanne Bean-Mayberry; Nataria T Joseph; Lauren E Thompson; Jessica L Zuchowski; Stacie L Daugherty; Elizabeth M Yano; P Michael Ho Journal: J Womens Health (Larchmt) Date: 2017-05-12 Impact factor: 2.681
Authors: Young Erben; James F Meschia; Donald V Heck; Fayaz A Shawl; Minerva Mayorga-Carlin; George Howard; Kenneth Rosenfield; John D Sorkin; Thomas G Brott; Brajesh K Lal Journal: Catheter Cardiovasc Interv Date: 2021-08-13 Impact factor: 2.585
Authors: Marlies M Kok; Marieke G M Weernink; Clemens von Birgelen; Anneloes Fens; Liefke C van der Heijden; Janine A van Til Journal: Catheter Cardiovasc Interv Date: 2017-05-04 Impact factor: 2.692
Authors: Andrija Matetic; Warkaa Shamkhani; Muhammad Rashid; Annabelle Santos Volgman; Harriette G C Van Spall; Thais Coutinho; Laxmi S Mehta; Garima Sharma; Purvi Parwani; Mohamed Osama Mohamed; Mamas A Mamas Journal: CJC Open Date: 2021-07-01
Authors: Jessica Potts; Alex Sirker; Sara C Martinez; Martha Gulati; Mirvat Alasnag; Muhammad Rashid; Chun Shing Kwok; Joie Ensor; Danielle L Burke; Richard D Riley; Lene Holmvang; Mamas A Mamas Journal: PLoS One Date: 2018-09-04 Impact factor: 3.240